Skip to main content
Media RelationsInvestor RelationsHome
Logo SphingotecLogo Sphingotec

The Biomarker Company

SphingoTec develops and markets innovative IVD solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.

Our innovative biomarkers address diagnostically underserved acute and critical care conditions such as acute kidney injury, sepsis, and acute heart failure. The solutions we have created combine scientific discoveries with medical research and robust technologies to support clinicians in improving patient care. We work with internationally leading academic and non-academic medical centers as well as global IVD and pharma companies to bring these innovations closer to the patients. 

Innovative diagnostic solutions for unmet medical needs

Wide adoption

Commercial opportunities

We collaborate with a wide range of industry partners to convey the value of our biomarker innovations in clinical diagnostics and drug development.

Read more

Product portfolio

Biomarker-based diagnostics

We make our proprietary biomarkers available as CE IVD microtiter plate assays, a well-established technique suited for laboratories. 

Read more

From bench to bedside

Biomarker innovations

The main mortality drivers in intensive care units are diagnostic blind spots. We pave the way for early intervention and personalized medicine in acute and critical care with innovative biomarkers.

 

Read more

Latest News

View all News

06. May 2025

Boditech Med and SphingoTec Announce Launch of AFIAS penKid® Assay for Kidney Function Diagnostics

Boditech Med Inc. and SphingoTec GmbHtoday announced the commercial launch of the AFIAS sphingotest® penKid® assay.
Read more
16. April 2025

Beyond Creatinine: First Real-World Evidence Highlights Proenkephalin A 119–159 (penKid) as a Valuable Kidney Function Biomarker

Proenkephalin A 119–159 (penKid) has been successfully integrated into daily practice in intensive care unit (ICU), demonstrating its effectiveness in assessing kidney function and predicting acute kidney injury (AKI) in over 4,000 patients.
Read more
09. January 2025

Assessing Post-Cardiac Surgery Kidney Recovery Through PenKid's Emerging Role in Renal Replacement Therapy Decisions

Results from the first prospective study, conducted at the Medical University of Vienna, demonstrating penKid as a discriminatory biomarker for successful liberation from CRRT in cardiac surgery patients with acute kidney injury.
Read more

Events & Expos

View all Events

04. - 06. December 2024

15:21 - 15:22

Hamburg, Germany

24. KONGRESS DER DEUTSCHEN INTERDISZIPLINÄREN VEREINIGUNG FÜR INTENSIV- UND NOTFALLMEDIZIN E.V. (DIVI)

The 24th Congress of The German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI) is a conference dedicated to practical and scientific topics related to intensive care and…

Read more
11. - 13. June 2024

15:21 - 15:22

Vicenza, Italy

42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology 2024

In the 2024 edition of the course, special attention will be placed on the new developments in the areas of technology, pharmacology, clinical trials and consensus definitions in critical care…

Read more
19. - 22. March 2024

15:21 - 15:22

Brussels, Belgium

43rd International Symposium on Intensive Care and Emergency Medicine (ISICEM)

The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Université Libre de…

Read more

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now

Follow our Journey on Social Media